AAAAAA

   
Results: 1-8 |
Results: 8
Don't breathe the air: Pollution and US environmental politics, 1945-1970.
Authors: Luger, S
Citation: S. Luger, Don't breathe the air: Pollution and US environmental politics, 1945-1970., J AM HIST, 88(2), 2001, pp. 736-736
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation
Authors: Mathias, C Mick, R Grupp, S Duffy, K Harris, F Laport, G Stadtmauer, E Luger, S Schuster, S Wasik, MA Porter, DL
Citation: C. Mathias et al., Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation, J HEMATH ST, 9(3), 2000, pp. 393-400
A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma
Authors: Stiff, P Gingrich, R Luger, S Wyres, MR Brown, RA LeMaistre, CF Perry, J Schenkein, DP List, A Mason, JR Bensinger, W Wheeler, C Freter, C Parker, WRL Emmanouilides, C
Citation: P. Stiff et al., A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma, BONE MAR TR, 26(5), 2000, pp. 471-481
c-myb antisense oligonucleotide therapeutics for hematologic malignancies
Authors: Luger, S
Citation: S. Luger, c-myb antisense oligonucleotide therapeutics for hematologic malignancies, METH MOL M, 35, 2000, pp. 577-592
Pharmacokinetics, dosimetry, and initial therapeutic results with I-131- and In-111-/Y-90-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
Authors: Juweid, ME Stadtmauer, E Hajjar, G Sharkey, RM Suleiman, S Luger, S Swayne, LC Alavi, A Goldenberg, DM
Citation: Me. Juweid et al., Pharmacokinetics, dosimetry, and initial therapeutic results with I-131- and In-111-/Y-90-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma, CLIN CANC R, 5(10), 1999, pp. 3292S-3303S
Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
Authors: Tsai, DE Moore, HCF Hardy, CL Porter, DL Loh, EY Vaughn, DJ Luger, S Schuster, SJ Stadtmauer, EA
Citation: De. Tsai et al., Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation, BONE MAR TR, 24(5), 1999, pp. 521-526
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I (+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia
Authors: Zhang, QA Lee, B Korecka, M Li, G Weyland, C Eck, S Gessain, A Arima, N Lessin, SR Shaw, LM Luger, S Kamoun, M Wasik, MA
Citation: Qa. Zhang et al., Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I (+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia, LEUK RES, 23(4), 1999, pp. 373-384
Calcium signaling induces acquisition of dendritic cell characteristics inchronic myelogenous leukemia myeloid progenitor cells
Authors: Engels, FHC Koski, GK Bedrosian, I Xu, SW Luger, S Nowell, PC Cohen, PA Czerniecki, BJ
Citation: Fhc. Engels et al., Calcium signaling induces acquisition of dendritic cell characteristics inchronic myelogenous leukemia myeloid progenitor cells, P NAS US, 96(18), 1999, pp. 10332-10337
Risultati: 1-8 |